Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Efstathios Kastritis, Evangelos Terpos & Meletios A Dimopoulos. (2013) Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy 14:11, pages 1477-1495.
Read now
Read now
Elif Suyanı, Gülsan Türköz Sucak, Yasemin Erten, Merih Kızıl Çakar, Gülay Ulusal, Münci Yağcı & Rauf Haznedar. (2012) Evaluation of Multiple Myeloma Patients Presenting with Renal Failure in a University Hospital in the Year 2010. Renal Failure 34:2, pages 257-262.
Read now
Read now
Mahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S Mitsiades, Irene M Ghobrial, Nikhil Munshi, Kenneth C Anderson & Paul G Richardson. (2012) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology 5:1, pages 51-68.
Read now
Read now
Isik Kaygusuz, Tayfur Toptas, Fergun Aydin, Ant Uzay, Tulin Firatli-Tuglular & Mahmut Bayik. (2011) Bortezomib in patients with renal impairment. Hematology 16:4, pages 200-208.
Read now
Read now
R. Schots, M. Delforge, M. André, G. Bries, J. Caers, H. Demuynck, B. De Prijck, H. De Samblanx, A. Kentos, N. Meuleman, F. Offner, M.C. Vekemans, I. Vande Broek, J. Van Droogenbroeck, A. Van de Velde, K.L. Wu & C. Doyen. (2010) THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA. Acta Clinica Belgica 65:4, pages 252-264.
Read now
Read now
Selmin A Ataergin, Tamila Kindwall-Keller, Nathan A Berger & Hillard M Lazarus. (2009) New generation pharmacotherapy in elderly multiple myeloma patients. Expert Opinion on Pharmacotherapy 10:1, pages 81-98.
Read now
Read now
Paul G Richardson, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Nikhil Munshi & Kenneth C Anderson. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy 8:7, pages 1053-1072.
Read now
Read now
Morie A. Gertz. (2008) Current therapy of myeloma induced renal failure. Leukemia & Lymphoma 49:5, pages 833-834.
Read now
Read now
Articles from other publishers (57)
Natàlia Ramos Terrades, Alicia Senin, Maria A Azancot, Mercedes Gironella, Nestor Toapanta, Sheila Bermejo, Lucia Martin, Fernando Caravaca-Fontán, Clara Cuellar, Joaquin Martínez-Lopez, Eva Rodríguez, Oriol Bestard & Maria Jose Soler. (2023) Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view. Clinical Kidney Journal 16:6, pages 1014-1021.
Crossref
Crossref
Sumana Kundu, Surajkumar B Jha, Ana P Rivera, Gabriela V Flores Monar, Hamza Islam, Sri Madhurima Puttagunta, Rabia Islam & Ibrahim Sange. (2022) Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Cureus.
Crossref
Crossref
Maiya Valerevna Firsova, L.P. Mendeleeva, M.V. Solov’ev, D.A. Mironova, L.A. Kuzmina & V.G. Savchenko. (2022) Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma with Renal Impairment. Clinical oncohematology 15:1, pages 97-106.
Crossref
Crossref
M. V. Firsova, L. P. Mendeleeva, M. V. Solovev, I. G. Rekhtina, O. S. Pokrovskaya, E. S. Urnova, N. P. Soboleva, V. N. Dvirnyk, G. A. Klyasova, L. A. Kuzmina & V. G. Savchenko. (2020) Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure. Terapevticheskii arkhiv 92:7, pages 70-76.
Crossref
Crossref
Kenar D. Jhaveri & Mitchell H. Rosner. 2020. Chronic Renal Disease. Chronic Renal Disease
899
917
.
Punit Yadav, Paul Cockwell, Mark Cook, Jennifer Pinney, Hannah Giles, Yu Sandar Aung, David Cairns, Roger G. Owen, Faith E. Davies, Graham H. Jackson, J. Anthony Child, Gareth J. Morgan & Mark T. Drayson. (2018) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrology 19:1.
Crossref
Crossref
I G Rekhtina & L P Mendeleeva. (2017) Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs. Terapevticheskii arkhiv 89:7, pages 112-117.
Crossref
Crossref
Mojgan Esparvarinha, Hamid Nickho, Hamed Mohammadi, Leili Aghebati-Maleki, Jalal Abdolalizadeh & Jafar Majidi. (2017) The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomedicine & Pharmacotherapy 91, pages 632-644.
Crossref
Crossref
Wanqiu Zhu & Wenming Chen. (2016) Bortezomib-based treatment for multiple myeloma patients with renal impairment. Medicine 95:46, pages e5202.
Crossref
Crossref
Punit Yadav, Colin A. Hutchison, Kolitha Basnayake, Stephanie Stringer, Mark Jesky, Lesley Fifer, Kym Snell, Jennifer Pinney, Mark T. Drayson, Mark Cook & Paul Cockwell. (2016) Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. European Journal of Haematology 96:6, pages 610-617.
Crossref
Crossref
Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Erasmia Psimenou, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Charis Matsouka, Despoina Mparmparousi, Dimitra Gika, Eftychia Kafantari, Dimitrios Ziogas, Despoina Fotiou, Ioannis Panagiotidis, Evangelos Terpos & Efstathios Kastritis. (2016) Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. American Journal of Hematology 91:5, pages 499-502.
Crossref
Crossref
Punit Yadav, Mark Cook & Paul Cockwell. (2016) Current Trends of Renal Impairment in Multiple Myeloma. Kidney Diseases 1:4, pages 241-257.
Crossref
Crossref
M. B. Agarwal. (2015) Multiple Myeloma: Treatment is Getting Individualized. Indian Journal of Hematology and Blood Transfusion 32:1, pages 3-9.
Crossref
Crossref
Saulius K. Girnius, Saem Lee, Suman Kambhampati, Michal G. Rose, Abid Mohiuddin, Antoun Houranieh, Abraham Zimelman, Terrence Grady, Paulette Mehta, Caroline Behler, Teresa G. Hayes, Yvonne A. Efebera, Rao H. Prabhala, Andrew Han, Sarvari V. Yellapragada, Catherine E. Klein, Garson D. Roodman, Alan Lichtenstein & Nikhil C. Munshi. (2015) A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. British Journal of Haematology 169:1, pages 36-43.
Crossref
Crossref
Norbert Grzasko, Marta Morawska & Marek Hus. (2015) Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment. Clinical Lymphoma Myeloma and Leukemia 15:4, pages 187-198.
Crossref
Crossref
Kenar D. Jhaveri & Mitchell H. Rosner. 2015. Chronic Renal Disease. Chronic Renal Disease
571
584
.
Hyun Chul WhangEun Sil KohJeong Gwan KimSungjin ChungSeok Joon ShinCheol Whee ParkYoon Sik Chang. (2014) Risk Factors and Reversibility of Renal Failure in Patients with Newly Diagnosed Multiple Myeloma. Korean Journal of Medicine 86:2, pages 190.
Crossref
Crossref
Francis Buadi & Asher Chanan Khan. 2014. Multiple Myeloma. Multiple Myeloma
159
177
.
Eliot C. Heher, Helmut G. Rennke, Jacob P. Laubach & Paul G. Richardson. (2013) Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology 8:11, pages 2007-2017.
Crossref
Crossref
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, Marc Andrea, Thomas Schliwa, Simone Heyn, Marion Schmalfeld, Thomas Edelmann, Cornelia Becker, Franz Albert Hoffmann, Andreas Schwarzer, Ute Kreibich, Matthias Egert, Runa Stiegler, Rainer Krahl, Yvonne Remane, Anette Bachmann, Tom Lindner, Lorenz Weidhase, Sirak Petros, Stefan Fricke, Vladan Vucinic, Haifa Al Ali & Dietger Niederwieser. (2013) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of Cancer Research and Clinical Oncology 139:11, pages 1937-1946.
Crossref
Crossref
M A Dimopoulos, M Roussou, M Gkotzamanidou, N Nikitas, E Psimenou, D Mparmparoussi, C Matsouka, M Spyropoulou-Vlachou, E Terpos & E Kastritis. (2012) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27:2, pages 423-429.
Crossref
Crossref
Morie A. Gertz & Robert A. Kyle. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
729
750
.
A. Davenport & G. Merlini. (2012) Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrology Dialysis Transplantation 27:10, pages 3713-3718.
Crossref
Crossref
Frank Bridoux & Jean-Paul Fermand. (2012) Optimizing Treatment Strategies in Myeloma Cast Nephropathy: Rationale for a Randomized Prospective Trial. Advances in Chronic Kidney Disease 19:5, pages 333-341.
Crossref
Crossref
Esftathios Kastritis, Meletios A. Dimopoulos & Joan Bladé. (2012) Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. Advances in Chronic Kidney Disease 19:5, pages 312-323.
Crossref
Crossref
Grzegorz Charliński, Grzegorz Ostrowski & Elżbieta Wiater. (2012) Leki immunomodulujące oraz inhibitory proteasomów w leczeniu chorych na szpiczaka plazmocytowego z niewydolnością nerek. Acta Haematologica Polonica 43:2, pages 173-186.
Crossref
Crossref
Asher A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig & Meletios A. Dimopoulos. (2012) Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. Clinical Cancer Research 18:8, pages 2145-2163.
Crossref
Crossref
Colin A. Hutchison, Joan Bladé, Paul Cockwell, Mark Cook, Mark Drayson, Jean-Paul Fermand, Efstathios Kastritis, Robert Kyle, Nelson Leung, Sonia Pasquali & Christopher Winearls. (2012) Novel approaches for reducing free light chains in patients with myeloma kidney. Nature Reviews Nephrology 8:4, pages 234-243.
Crossref
Crossref
Fortunato MorabitoMassimo GentileCarla MazzoneDavide RossiFrancesco Di RaimondoSara BringhenRoberto RiaMassimo OffidaniFrancesca PatriarcaChiara NozzoliMaria Teresa PetrucciGiulia BenevoloIolanda VincelliTommasina GuglielmelliMariella GrassoRoberto MarascaLuca BaldiniVittorio MontefuscoPellegrino MustoNicola CascavillaIgnazio MajolinoCaterina Musolino, Michele Cavo, Mario BoccadoroAntonio Palumbo. (2011) Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 118:22, pages 5759-5766.
Crossref
Crossref
Éric Moumas, William Hanf, Estelle Desport, Julie Abraham, Sébastien Delbès, Céline Debiais, Laurence Lacotte-Thierry, Guy Touchard, Arnaud Jaccard, Jean-Paul Fermand & Frank Bridoux. (2011) Actualités dans le traitement du myélome avec insuffisance rénale. Néphrologie & Thérapeutique 7:6, pages 457-466.
Crossref
Crossref
Jennifer M. Bird, Roger G. Owen, Shirley D?Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low & Judith Behrens. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology 154:1, pages 32-75.
Crossref
Crossref
R. Schots. (2011) Recent advances in myeloma treatment. Transfusion and Apheresis Science 44:2, pages 223-229.
Crossref
Crossref
Hannes Neuwirt, Michael Rudnicki, Herbert Schramek & Gert Mayer. (2014) Monoclonal Light Chains and the Kidney. Nephrology Research & Reviews 3:1, pages 13-22.
Crossref
Crossref
Shinichi Nariyama, Masahito Iida, Hiroomi Kasumoto, Shigeki Masuda, Yoshie Itou, Masako Tokuoka, Keiko Himuro, Hideshi Kaneko, Tatsuhisa Sada, Amana Takahashi & Takeshi Nakanishi. (2011) The combination of bortezomib and dexamethasone therapy led to the discontinuation of dialysis therapy in a multiple myeloma patient developing severe acute renal failure. Nihon Toseki Igakkai Zasshi 44:10, pages 1023-1029.
Crossref
Crossref
Eugenio Piro & Stefano Molica. (2011) A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence. Acta Haematologica 126:3, pages 163-168.
Crossref
Crossref
Morie A. Gertz & Raymond Comenzo. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
135
148
.
Heinz LudwigZdenek AdamRoman HajekRichard GreilElena TóthováFelix KeilEva Maria AutzingerJosef ThalerHeinz GisslingerAlois LangMiklós EgyedIrene WomastekNiklas Zojer. (2010) Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. Journal of Clinical Oncology 28:30, pages 4635-4641.
Crossref
Crossref
Eliot C. HeherNelson B. GoesThomas R. SpitzerNoopur S. RajeBenjamin D. Humphreys, Kenneth C. Anderson & Paul G. Richardson. (2010) Kidney disease associated with plasma cell dyscrasias. Blood 116:9, pages 1397-1404.
Crossref
Crossref
María-Victoria Mateos. (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treatment Reviews 36, pages S24-S32.
Crossref
Crossref
Sagar Lonial. (2010) Presentation and risk stratification – improving prognosis for patients with multiple myeloma. Cancer Treatment Reviews 36, pages S12-S17.
Crossref
Crossref
Fortunato Morabito, Massimo Gentile, Stefania Ciolli, Maria T. Petrucci, Sara Galimberti, Giuseppe Mele, Antonio F. Casulli, Donato Mannina, Eugenio Piro, Graziella Pinotti, Salvatore Palmieri, Lucio Catalano, Vincenzo Callea, Massimo Offidani, Pellegrino Musto, Sara Bringhen, Luca Baldini, Patrizia Tosi, Francesco Di Raimondo, Mario Boccadoro, Antonio Palumbo & Michele Cavo. (2010) Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology 84:3, pages 223-228.
Crossref
Crossref
Kosei Matsue, Hideaki Fujiwara, Kan-Ichi Iwama, Shun-Ichi Kimura, Masayuki Yamakura & Masami Takeuchi. (2009) Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Annals of Hematology 89:3, pages 291-297.
Crossref
Crossref
Efstathios KastritisAshutosh D. WechalekarMeletios A. DimopoulosGiampaolo MerliniPhilip N. HawkinsVittorio PerfettiJulian D. GillmoreGiovanni Palladini. (2010) Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology 28:6, pages 1031-1037.
Crossref
Crossref
Donald J. AbrahamMarie Wehenkel & Kyung Bo Kim. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
175
190
.
Dominique D. Benoit & Eric A. Hoste. (2010) Acute Kidney Injury in Critically Ill Patients with Cancer. Critical Care Clinics 26:1, pages 151-179.
Crossref
Crossref
Meletios A. DimopoulosPaul G. RichardsonRudolf SchlagNuriet K. KhuagevaOfer ShpilbergEfstathios KastritisMartin KropffMaria T. PetrucciMichel DelforgeJulia AlexeevaRik SchotsTamás MassziMaria-Victoria MateosWilliam DeraedtKevin LiuAndrew CakanaHelgi van de VeldeJesús F. San Miguel. (2009) VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. Journal of Clinical Oncology 27:36, pages 6086-6093.
Crossref
Crossref
Jian Li, Dao-Bin Zhou, Li Jiao, Ming Hui Duan, Wei Zhang, Yong Qiang Zhao & Ti Shen. (2009) Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment. Clinical Lymphoma and Myeloma 9:5, pages 394-398.
Crossref
Crossref
Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Flora Zagouri, Magdalini Migkou, Charis Matsouka, Despina Barbarousi, Dimitrios Christoulas, Erasmia Primenou, Irini Grapsa, Evangelos Terpos & Efstathios Kastritis. (2009) Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma and Myeloma 9:4, pages 302-306.
Crossref
Crossref
Lie-Ping GUO, Fan ZHOU, Sheng-Ling YANG, Wei WEI, Yi-Zi ZHANG & Jian HOU. (2009) Bortezomib in treatment of a newly diagnosed multiple myeloma patient with renal failure. Academic Journal of Second Military Medical University 29:5, pages 603-604.
Crossref
Crossref
Sagar Lonial & Jamie Cavenagh. (2009) Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology 145:6, pages 681-708.
Crossref
Crossref
Monique P. Curran & Kate McKeage. (2009) Bortezomib. Drugs 69:7, pages 859-888.
Crossref
Crossref
Eliot C. Heher, Thomas R. Spitzer & Nelson B. Goes. (2009) Light Chains: Heavy Burden in Kidney Transplantation. Transplantation 87:7, pages 947-952.
Crossref
Crossref
J. Drach. (2009) Novel therapeutic concepts in multiple myeloma. memo - Magazine of European Medical Oncology 2:S1, pages 5-9.
Crossref
Crossref
G. David Roodman. (2009) Therapeutic Options in Multiple Myeloma: Focus on Bortezomib. Clinical Medicine. Therapeutics 1, pages CMT.S2119.
Crossref
Crossref
Morie A. Gertz, Irene Ghobrial & Jean Luc-Harousseau. (2009) Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy. Biology of Blood and Marrow Transplantation 15:1, pages 46-52.
Crossref
Crossref
Daniel Man-Yuen Sze, Jian Hou & Lily Zhou. (2008) Newly developed effective anti-cancer drugs targeting multiple myeloma. Drug Development Research 69:7, pages 451-459.
Crossref
Crossref
M A Dimopoulos, E Kastritis, L Rosinol, J Bladé & H Ludwig. (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:8, pages 1485-1493.
Crossref
Crossref